Back

The SLCO1B1 c.521 T > C variant is not associated with muscular symptoms or PCSK9-inhibitor prescription in patients with severe hypercholesterolemia

29 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Lipids (1) Lipids ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Lukas Galli

Medical University of Vienna, Vienna (Austria)

4 More presentations in this session

Presentation thumbnail
Predictive value of blood count derived inflammatory markers for LDL cholesterol target achievement after STEMI
Doctor V. Halatiu (Targu Mures, RO)
Abstract Slides Video
Presentation thumbnail
Treatment quality in patients with familial hypercholesterolemia in Denmark
Doctor J. Knold (Odense, DK)
Abstract Slides Video
Presentation thumbnail
Suboptimal LDL-C control despite high statin use: insights from the LAI-LCARE survey on secondary CAD prevention in India
Doctor K. Mahajan (Mandi, IN)
Abstract Slides Video
Presentation thumbnail
Early post-discharge follow-up improves lipid control and reduces cardiovascular risk in ACS patients: insights from a tertiary cardiac centre
Doctor A. Elkammash (Bristol, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Lipids (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Session
Pharmacogenetics: a tool to guide clinical decisions
thumbnail
Congress Presentation
The association between the response of lipid-lowering agents and monogenic variants of familiar hypercholesteremia in Taiwan
thumbnail
Congress Presentation
Cardiovascular risk among individuals with and without genetic mutation for familial hypercholesterolemia: A long-term follow-up study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources